KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Income (2020 - 2023)

Historic Net Income for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.

  • AbCellera Biologics' Net Income fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$47.2 million, marking a year-over-year increase of 6348.95%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' Net Income is -$47.2 million, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' Net Income peaked at $168.6 million during Q1 2022, and registered a low of -$47.2 million during Q4 2023.
  • Its 4-year average for Net Income is $20.5 million, with a median of -$2.5 million in 2020.
  • Examining YoY changes over the last 5 years, AbCellera Biologics' Net Income showed a top increase of 570062.11% in 2021 and a maximum decrease of 69391.01% in 2021.
  • Over the past 4 years, AbCellera Biologics' Net Income (Quarter) stood at $161.2 million in 2020, then plummeted by 62.8% to $59.9 million in 2021, then tumbled by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
  • Its last three reported values are -$47.2 million in Q4 2023, -$28.6 million for Q3 2023, and -$30.5 million during Q2 2023.